比较狄诺塞麦和双膦酸盐在原发性骨质疏松症中的应用

比较狄诺塞麦和双膦酸盐在原发性骨质疏松症中的应用

Denosumab is a new anti-osteoporosis drug that acts on the receptor activator of nuclear factor-κB ligand, while bisphosphonates are anti-bone resorption drugs that have been widely used. Denosumab and bisphosphonates have different mechanisms of action, but both have the effects of reducing the risk of fractures, increasing bone mineral density, and reducing the levels of bone turnover markers, and are generally safe in clinical applications. This review compares the two drugs in terms of mechanism of action, treatment effect, adverse reactions, application in patients with renal insufficiency, and drug compliance.

狄诺塞麦是作用于核因子-κB受体活化因子配体的新型抗骨质疏松药物,而双膦酸盐则是已得到广泛应用的抗骨吸收药物。狄诺塞麦和双膦酸盐有不同的作用机制,但都具有降低骨折风险、增加骨密度、降低骨转换标志物水平的作用,且临床应用大体安全。本综述从作用机制、治疗效果、不良反应、在肾功能不全患者中的应用及药物依从性五个方面分别对上述两种药物进行比较。